|
|
Post by mnholdem on Jul 30, 2018 20:45:04 GMT -5
sayhey24
The Big Dog behind the GLP-1s push is Ralph DeFronzo, the same guy who brought us metformin and who now says its the biggest waste in T2 treatment. He thinks combining GLP-1 with Actos is a great idea and short term results in the Qatar study are good and show beta cell regeneration. At the same time Ralph is talking about the SGLT-2 amputation risks. If you want to stop CVD - stop the spike and nothing does it better than afrezza. Doing it with GLP1s and TZDs are down right dangerous. If you stop the spike with afrezza you don't need the SGLT-2s to piss out the sugar.Read more: mnkd.proboards.com/thread/10272/reality-situation#ixzz5Mn9F79aM--- Shortly after the announcement that Sanofi was ending its agreement with MannKind, I was discussing the potential of partnering with MannKind with Takeda CEO Christophe Weber. He told me that the BoD at Takeda had decided to end all further R&D in diabetes drugs. IMO, the judgement against Takeda because of multiple deaths related to Actos and the subsequent $2.4 billion settlement was the primary reason for their change in direction. As I recall, judgment stated that Takeda failed to sufficiently warn patients about the dangers of incorrectly dosing Actos45. Link: www.drugwatch.com/actos/lawsuits/Companies can try to make the argument that potential death isn't required to be on the label, but they can still be held legally accountable for withholding information about serious dangers of using their drug.
|
|
|
|
Post by mnholdem on Jul 30, 2018 20:21:06 GMT -5
An interesting choice of words. "Political capital" is synonymous with special interest groups that dump $$$ in various ways to influence decision makers. You might very well think that; I couldn't possibly comment. (Thank you Francis Urquhart) Hang on...are you calling me the "epitome of elegant evil"?  |
|
|
|
Post by mnholdem on Jul 30, 2018 20:11:34 GMT -5
An interesting choice of words you chose in your earlier post. "Political capital" is synonymous with special interest groups that dump $$$ in various ways to influence decision makers. Your implication is that the FDA/AACE can be bought. That might be true. But influence can also be channeled through relationships with key decision makers. David Kendall and MannKind's new Scientific Advisory Board are all-stars with heavy connections to the ADA and AACE, as well as diabetes advocacy organizations. MannKind Corporation's new CMO and the SAB have the kind of influence that money alone can't buy. In addition, if the ADA/AACE feel that these heavy hitters may expose some of the questionable methods behind various inclusions into the diabetes standard of care, they will likely steer clear of money-based influence peddling. There's an old adage that "a reputation which takes years to build can be destroyed in a single day". I really hope that the ADA and AACE start being held accountable for some of their past decisions.  |
|
|
|
Post by mnholdem on Jul 30, 2018 18:19:45 GMT -5
It doesn’t matter to me which horse pulls the “ultra” wagon to the barn.
|
|
|
|
Post by mnholdem on Jul 30, 2018 16:56:19 GMT -5
Frankly it just may get its own class. Before agedhippie can chime in, there is plenty of clinical evidence about the effect of faster insulin on first phase insulin release, signaling the liver to shut down glucose production. It's something RAA insulin tries to achieve by dosing pre-meal but doesn't accomplish. If anyone can convince the ADA/AACE that an ultra rapid-acting classification is merited, I think it's David Kendall MD.
|
|
|
|
Post by mnholdem on Jul 30, 2018 11:30:17 GMT -5
The Carlyle Group are PE so if they get involved in Mannkind that would pretty much be the end. They would want the whole company, and cheaply because there is no cash and they cannot load it up with debt. Their exit would have to be either turning the company around, or breaking it up and selling of the parts. They are unlikely to see the ROI in attempting to turn it around given where sales are three years after launch, and their BP contacts are unlikely to say good things. I believe you're spot on in that assessment. Over the weekend I did a little more digging into the newly-formed Phoenix Therapeutics company involving Bourne Partners & Carlyle, thinking there may be a connection since Bourne Partners formed the Tanner Group.
Jan 2016 NEW YORK, NY and CHARLOTTE, NC – Global alternative asset manager The Carlyle Group (NASDAQ: CG) announced today that it has formed a joint venture with Bourne Partners, a healthcare-focused investor, operator and investment banking firm, to build a global pharmaceutical platform. This new venture, known as Phoenix Therapeutics, will be owned by Carlyle Partners VI, a $13 billion U.S. buyout fund, with a minority investment from Bourne Partners. Leveraging the financial resources and experience of Carlyle and Bourne, Phoenix Therapeutics will look to operate a pharmaceutical platform built through acquisitions. Phoenix Therapeutics will consider a range of acquisitions, including product and asset acquisitions, corporate acquisitions and carve-outs.
Carlyle Partners VI
United States
Asset Class
U.S. Buyout
Launched in 2013 at $13.0 billion, this fund conducts leveraged buyout transactions in North America in targeted industries.
---
I haven't seen any further news whatsoever about Phoenix Therapeutics since this Jan-2016 press release so I no longer think that there is any connection with Carlyle related to the MannKind-Tanner Group agreement even though I thought it was worth exploring.
|
|
|
|
Post by mnholdem on Jul 30, 2018 9:54:06 GMT -5
Incidentally, Kent Kresa (MannKind's Chairman of the Board) used to be a senior advisor to The Carlyle Group.
On November 3, 2003, the Carlyle Group hired [Kent] Kresa as a Senior Advisor to its aerospace and defense group. Kresa commented on his hiring by stating, “I’ve known the Carlyle executives for many years and have an abiding respect for their approach and judgment. For years, Carlyle has played a significant role in the aerospace and defense market. Carlyle has a straightforward approach to its business and delivers on its promises. I’m delighted to be associated with them.”
Source: en.wikipedia.org/wiki/Kent_Kresa
|
|
|
|
Post by mnholdem on Jul 30, 2018 9:50:52 GMT -5
I'm also interested in how much The Carlyle Group puts out in invested capital. 
|
|
|
|
Post by mnholdem on Jul 29, 2018 16:56:36 GMT -5
I was just thinking that those words Pfeffer spoke may one day be considered prophetic. What's valuable about this company is the Technosphere drug delivery platform. But lack of cash is what's preventing more drugs from entering the development pipeline at the present time.
Revenue and/or funding will change that situation. TreT is a ways from FDA approval, so the burden falls on building sales of Afrezza. We don't know what all Dr. Kendall is doing but we're hearing bits and pieces from various sources that Afrezza is generating attention among the diabetes treatment community.
MannKind has already published which diabetes conferences they'll be presenting at this year, but I think there's much more going on behind the scenes that shareholders are not aware of. For example, Dr. Kendall getting an invitation to speak about Technosphere insulin at two major universities is an event shareholders would be in the dark about if MC hadn't mentioned it to his Twitter followers.
It wasn't a material event so he can disclose the information. When it comes to material events, we simply won't hear about them until agreements are signed.
|
|
|
|
Post by mnholdem on Jul 29, 2018 16:20:23 GMT -5
Multi-channel marketing. Good! Less expensive, too. |
|
|
|
Post by mnholdem on Jul 29, 2018 16:17:48 GMT -5
Example: During the Oct-2017 share price rally to nearly $7, I sold about 1/3 of my $2 call options at 929% return after commission. That was with the share price under $7.
I don't want to put words into Nate's mouth (or should I say ink into his pen) but if you bought MNKD at $1.50 on Monday and share price rallies to $7-$10 by EOY, what's your ROI? Isn't that the point Nate Pile is making?
|
|
|
|
Post by mnholdem on Jul 29, 2018 16:00:27 GMT -5
morgieporgie you've made your point. Move on...this repetitiveness against other viewpoints is beginning to resemble harassment. Thank you!
|
|
|
|
Post by mnholdem on Jul 29, 2018 15:42:28 GMT -5
If Nate stated a 300% it would be from the share price the date he wrote it. Investors' returns will vary depending on their individual average share price. BTW, call options could return much more than 300%. |
|
|
|
Post by mnholdem on Jul 29, 2018 15:36:43 GMT -5
There are multiple countries that allow drugs to be mail-ordered from the USA if the drugs are FDA approved.
|
|
|
|
Post by mnholdem on Jul 29, 2018 10:58:21 GMT -5
I point out that both sales and insurance coverage have improved significantly, while Barnstormer says the situation is "desperate," that a pig wearing lipstick is still a pig, and that the next earnings call will probably be a "disaster." And I'm the one who's a "negative person?" IMO a smart investor always tries to assess the situation with a critical eye. The cash situation should be considered dire in the absence of news from management. It’s the same situation with sales growth. An investor who points this out should not automatically be labeled as a negative person. Facts are neither negative nor positive. CEO often paint an optimistic picture but that’s part of the job. An investor with a critical eye may notice that, even though sales have been slowly increasing since Michael was hired as Chief Commercial Officer, acceptance of Afrezza has been dismal compared to weekly prescriptions of Novolog/Humalog. Is that a negative statement? I don’t think so. It’s simply a fact. I suggest lightening up on posters who comment about risks. Risk is always present. Just read the Risks section of every 10-K filing. |
|
